Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from ...

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

About one out of every eight adults in the U.S. has taken a GLP-1 medication, such as Trulicity, Ozempic, Rybelsus or Mounjaro — and half of these people are still ...